Dear Editor,Systemic chemotherapy is hindered for the treatment of advanced HCC,largely due to the multidrug-resistance phenotype.1 One of the major mechanisms of drug resistance,increased drug efflux,is mediated by v...Dear Editor,Systemic chemotherapy is hindered for the treatment of advanced HCC,largely due to the multidrug-resistance phenotype.1 One of the major mechanisms of drug resistance,increased drug efflux,is mediated by various membrane transporters.ABCB1(MDR1)is one of the most extensively studied members of the ATP-binding cassette family and has been shown to be elevated in multiple tumor types.2 However,most clinical trials with ABCB1 inhibitors failed to reach the desired endpoints,which calls for an in-depth understanding of ABCB1 gene regulation.展开更多
基金supported by the National Natural Science Foundation of China(Nos.81572349,81872080)Jiangsu Provincial Medical Talent(ZDRCA 2016055)+1 种基金the Science and Technology Department of Jiangsu Province(BK20181148)the Priority Academic Program Development of Jiangsu Higher Education Institutions(PAPD).
文摘Dear Editor,Systemic chemotherapy is hindered for the treatment of advanced HCC,largely due to the multidrug-resistance phenotype.1 One of the major mechanisms of drug resistance,increased drug efflux,is mediated by various membrane transporters.ABCB1(MDR1)is one of the most extensively studied members of the ATP-binding cassette family and has been shown to be elevated in multiple tumor types.2 However,most clinical trials with ABCB1 inhibitors failed to reach the desired endpoints,which calls for an in-depth understanding of ABCB1 gene regulation.
